Dianthus Therapeutics, Inc. (NASDAQ:DNTH – Free Report) – Research analysts at Cantor Fitzgerald lifted their FY2025 EPS estimates for shares of Dianthus Therapeutics in a report issued on Thursday, March 13th. Cantor Fitzgerald analyst P. Stavropoulos now forecasts that the company will earn ($3.16) per share for the year, up from their prior estimate of ($3.46). The consensus estimate for Dianthus Therapeutics’ current full-year earnings is ($2.61) per share.
Dianthus Therapeutics (NASDAQ:DNTH – Get Free Report) last issued its quarterly earnings data on Tuesday, March 11th. The company reported ($0.81) EPS for the quarter, topping analysts’ consensus estimates of ($0.85) by $0.04. The company had revenue of $1.33 million for the quarter, compared to analysts’ expectations of $1.40 million. Dianthus Therapeutics had a negative return on equity of 21.68% and a negative net margin of 1,250.32%.
Get Our Latest Stock Report on Dianthus Therapeutics
Dianthus Therapeutics Trading Up 0.2 %
DNTH stock opened at $21.33 on Monday. The company has a market capitalization of $631.30 million, a P/E ratio of -8.53 and a beta of 1.82. The firm has a 50 day simple moving average of $22.54 and a 200-day simple moving average of $24.81. Dianthus Therapeutics has a twelve month low of $18.13 and a twelve month high of $33.77.
Institutional Investors Weigh In On Dianthus Therapeutics
Institutional investors have recently modified their holdings of the business. Quest Partners LLC increased its holdings in Dianthus Therapeutics by 112,400.0% in the third quarter. Quest Partners LLC now owns 1,125 shares of the company’s stock valued at $31,000 after purchasing an additional 1,124 shares during the last quarter. Charles Schwab Investment Management Inc. grew its position in shares of Dianthus Therapeutics by 142.0% during the 3rd quarter. Charles Schwab Investment Management Inc. now owns 165,929 shares of the company’s stock worth $4,543,000 after buying an additional 97,362 shares during the period. MetLife Investment Management LLC increased its stake in shares of Dianthus Therapeutics by 129.1% in the 3rd quarter. MetLife Investment Management LLC now owns 13,939 shares of the company’s stock valued at $382,000 after acquiring an additional 7,854 shares during the last quarter. Walleye Capital LLC acquired a new stake in shares of Dianthus Therapeutics in the 3rd quarter valued at approximately $821,000. Finally, Braidwell LP boosted its stake in Dianthus Therapeutics by 34.6% during the 3rd quarter. Braidwell LP now owns 493,687 shares of the company’s stock worth $13,517,000 after acquiring an additional 126,836 shares during the last quarter. Institutional investors and hedge funds own 47.53% of the company’s stock.
Dianthus Therapeutics Company Profile
Dianthus Therapeutics, Inc, a clinical-stage biotechnology company, develops complement therapeutics for patients with severe autoimmune and inflammatory diseases. It is developing DNTH103, a monoclonal antibody, which is in Phase 2 clinical trial, for the treatment of generalized myasthenia gravis, multifocal motor neuropathy, and chronic inflammatory demyelinating polyneuropathy.
See Also
- Five stocks we like better than Dianthus Therapeutics
- How to Calculate Inflation Rate
- How to Build the Ultimate Everything ETF Portfolio
- What Are Dividends? Buy the Best Dividend Stocks
- Dutch Bros or Starbucks: Which Coffee Stock Has More Growth?
- Are Penny Stocks a Good Fit for Your Portfolio?
- 3 Stocks With High ROE and Market-Beating Growth Potential
Receive News & Ratings for Dianthus Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Dianthus Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.